Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | KMO | O15229 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.47 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.47 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.47 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL110094 | 1.00 | TSHR (0.67) | TSHRSRD5A2MEN1KMT2AKDM4E | |
| SCHEMBL7543655 | 0.83 | CES2 (0.50) | TSHRSRD5A2MEN1KMT2AKDM4E | |
| SCHEMBL9812968 | 0.83 | TSHR (0.46) | TSHRSRD5A2MEN1KMT2AKDM4E | |
| SCHEMBL23484544 | 0.82 | AHR (0.58) | TSHRSRD5A2MEN1KMT2AKDM4E | |
| SCHEMBL6322177 | 0.82 | SRD5A2 (0.79) | TSHRSRD5A2MEN1KMT2AKDM4E | |
| SCHEMBL3184435 | 0.82 | TSHR (0.70) | TSHRSRD5A2MEN1KMT2AKDM4E | |
| SCHEMBL4286582 | 0.81 | HSP90AA1 (0.55) | TSHRSRD5A2KDM4EMAPTPOLB | |
| SCHEMBL9618406 | 0.81 | TSHR (0.45) | TSHRSRD5A2MEN1KMT2AKDM4E | |
| SCHEMBL101687 | 0.81 | TSHR (0.45) | TSHRSRD5A2MEN1KMT2AKDM4E | |
| SCHEMBL3566736 | 0.81 | TSHR (0.50) | TSHRSRD5A2KDM4EMAPTKMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119098067-A | Method for producing reverse osmosis membrane and reverse osmosis membrane produced thereby | 沃顿科技股份有限公司 | 2024-12-10 | — | — | CN | claimed |
| CN-117471012-A | Method for detecting related substances of p-chlorobenzoyl chloride by gas chromatography | 南京医科大学康达学院 | 2024-01-30 | — | — | CN | claimed |
| CN-114615823-A | Method for improving binding force between outer-layer conductive pattern of thick copper plate and printing ink | 常州澳弘电子股份有限公司 | 2022-06-10 | — | — | CN | claimed |
| CN-114432900-A | Preparation method of anti-pollution composite reverse osmosis membrane and anti-pollution composite reverse osmosis membrane prepared by same | 沃顿科技股份有限公司 | 2022-05-06 | — | — | CN | claimed |
| CN-112752837-B | Natural killer cells | 帝国理工学院创新有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20250206753-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | ABBVIE INC. | 2025-06-26 | — | — | US | disclosed |
| CN-116947688-B | Benzoyl hydrazine compounds, and preparation method and application thereof | 赣南师范大学 | 2025-06-03 | — | — | CN | disclosed |
| CN-120040420-A | Heterocyclic-pyrazole amine derivatives, preparation method thereof and application thereof in resisting tubercle bacillus infection | 中国医学科学院医药生物技术研究所 | 2025-05-27 | — | — | CN | disclosed |
| CN-119930563-A | Transient receptor potential cation channel TRPV3 inhibitor and application thereof | 苏中药业集团股份有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-116178337-B | Benzodiazepine compounds and their use as Rho kinase inhibitors | 成都奥睿药业有限公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-119638763-A | Gentiopicroside amide derivative, synthetic method and application | 甘肃中医药大学 | 2025-03-18 | — | — | CN | disclosed |
| CN-119098067-A | Method for producing reverse osmosis membrane and reverse osmosis membrane produced thereby | 沃顿科技股份有限公司 | 2024-12-10 | — | — | CN | disclosed |
| CN-116478134-A | SSRI/5-HT 1A Double-target antidepressant formylpiperidine compound and preparation method and application thereof | 上海医药工业研究院有限公司 | 2023-07-25 | — | — | CN | disclosed |
| CN-116178337-A | Benzodiazepine compounds and their use as Rho kinase inhibitors | 成都奥睿药业有限公司 | 2023-05-30 | — | — | CN | disclosed |
| CN-110734391-B | 2, 3-diketone indole compound and preparation method and application thereof | 山东大学 | 2023-05-02 | — | — | CN | disclosed |
| CN-115385902-A | Benzimidazole compound and preparation method and application thereof | 徐州医科大学 | 2022-11-25 | — | — | CN | disclosed |
| CN-114615823-A | Method for improving binding force between outer-layer conductive pattern of thick copper plate and printing ink | 常州澳弘电子股份有限公司 | 2022-06-10 | — | — | CN | disclosed |
| CN-114432900-A | Preparation method of anti-pollution composite reverse osmosis membrane and anti-pollution composite reverse osmosis membrane prepared by same | 沃顿科技股份有限公司 | 2022-05-06 | — | — | CN | disclosed |
| EP-3976620-A1 | FUSED HETEROCYCLIC DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2022-04-06 | — | — | EP | disclosed |
| CN-114258390-A | Glycolate oxidase inhibitors for disease treatment | 生物马林药物股份有限公司 | 2022-03-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250206753-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | VHL, BRDT, PAICS | TSHR 3988/4885SRD5A2 361/4885MEN1 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.